Literature DB >> 25583541

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Silvio E Inzucchi1, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25583541     DOI： 10.1007/s00125-014-3460-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  60 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 2.  Unleash metformin: reconsideration of the contraindication in patients with renal impairment.

Authors:  Wenya R Lu; Jennifer Defilippi; Amy Braun
Journal:  Ann Pharmacother       Date:  2013-10-10       Impact factor: 3.154

Review 3.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Authors:  Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas
Journal:  Ann Intern Med       Date:  2013-08-20       Impact factor: 25.391

4.  Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin.

Authors:  Kristina M Johnsson; Agata Ptaszynska; Bridget Schmitz; Jennifer Sugg; Shamik J Parikh; James F List
Journal:  J Diabetes Complications       Date:  2013-06-24       Impact factor: 2.852

Review 5.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

6.  Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

Authors:  M Monami; C Nardini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2013-12-29       Impact factor: 6.577

7.  Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

Authors:  Bruce Neal; Vlado Perkovic; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Peter Stein; Mehul Desai; Wayne Shaw; Joel Jiang; Frank Vercruysse; Gary Meininger; David Matthews
Journal:  Am Heart J       Date:  2013-06-24       Impact factor: 4.749

8.  Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

Authors:  Michaela Diamant; Michael A Nauck; Rimma Shaginian; James K Malone; Simon Cleall; Matthew Reaney; Danielle de Vries; Byron J Hoogwerf; Leigh MacConell; Bruce H R Wolffenbuttel
Journal:  Diabetes Care       Date:  2014-07-10       Impact factor: 19.112

9.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Michael Roden; Jianping Weng; Jens Eilbracht; Bruno Delafont; Gabriel Kim; Hans J Woerle; Uli C Broedl
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-09       Impact factor: 32.069

10.  SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.

Authors:  Yukihiro Chino; Yoshishige Samukawa; Soichi Sakai; Yasuhiro Nakai; Jun-ichi Yamaguchi; Takeo Nakanishi; Ikumi Tamai
Journal:  Biopharm Drug Dispos       Date:  2014-08-06       Impact factor: 1.627
View more
  213 in total

1.  Metformin: historical overview.

Authors:  Clifford J Bailey
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 2.  The pharmacogenetics of metformin.

Authors:  Jose C Florez
Journal:  Diabetologia       Date:  2017-08-03       Impact factor: 10.122

Review 3.  Metformin: clinical use in type 2 diabetes.

Authors:  Elizabeth Sanchez-Rangel; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 4.  Fixed ratio combinations of glucagon like peptide 1 receptor agonists with basal insulin: a systematic review and meta-analysis.

Authors:  Paraskevi Liakopoulou; Aris Liakos; Despoina Vasilakou; Eleni Athanasiadou; Eleni Bekiari; Kyriakos Kazakos; Apostolos Tsapas
Journal:  Endocrine       Date:  2017-04-12       Impact factor: 3.633

Review 5.  Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Authors:  Hong Sheng Cheng; Wei Ren Tan; Zun Siong Low; Charlie Marvalim; Justin Yin Hao Lee; Nguan Soon Tan
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

Review 6.  Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.

Authors:  Cristina Bianchi; Giuseppe Daniele; Angela Dardano; Roberto Miccoli; Stefano Del Prato
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 7.  [Insulin therapy of diabetes].

Authors:  Monika Lechleitner; Michael Roden; Raimund Weitgasser; Bernhard Ludvik; Peter Fasching; Friedrich Hoppichler; Alexandra Kautzky-Willer; Guntram Schernthaner; Rudolf Prager; Thomas C Wascher
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

8.  Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Authors:  Bo Ahrén
Journal:  Diabetologia       Date:  2015-03-20       Impact factor: 10.122

Review 9.  Exercise Prescription in Patients with Different Combinations of Cardiovascular Disease Risk Factors: A Consensus Statement from the EXPERT Working Group.

Authors:  Dominique Hansen; Josef Niebauer; Veronique Cornelissen; Olga Barna; Daniel Neunhäuserer; Christoph Stettler; Cajsa Tonoli; Eugenio Greco; Robert Fagard; Karin Coninx; Luc Vanhees; Massimo F Piepoli; Roberto Pedretti; Gustavo Rovelo Ruiz; Ugo Corrà; Jean-Paul Schmid; Constantinos H Davos; Frank Edelmann; Ana Abreu; Bernhard Rauch; Marco Ambrosetti; Simona Sarzi Braga; Paul Beckers; Maurizio Bussotti; Pompilio Faggiano; Esteban Garcia-Porrero; Evangelia Kouidi; Michel Lamotte; Rona Reibis; Martijn A Spruit; Tim Takken; Carlo Vigorito; Heinz Völler; Patrick Doherty; Paul Dendale
Journal:  Sports Med       Date:  2018-08       Impact factor: 11.136

10.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse
Journal:  Diabetologia       Date:  2018-12       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.